# Combination CurQD and Vedolizumab in Ulcerative Colitis

> **NCT07665294** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Ryan C Ungaro** · enrollment: 160 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** CurQD
- **DRUG:** Placebo
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT07665294
- **Lead sponsor:** Ryan C Ungaro
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-06-23
- **Final completion:** 2027-06-23
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665294, "Combination CurQD and Vedolizumab in Ulcerative Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*